BRCA2 reversion mutation confers resistance to olaparib in breast cancer

Shinya Yamamoto; Kei Kawashima; Yoshie Fujiwara; Shoko Adachi; Kazutaka Narui; Chiaki  Hosaka; Rina  Takahashi; Sho Tsuyuki; Makoto  Sugimori; Miki  Tanoshima; Mahato Sasamoto; Masanori Oshi; Akimitsu Yamada; Chikara  Kunisaki; Itaru Endo

doi:10.22541/au.167689089.99966238/v1

loading page

BRCA2 reversion mutation confers resistance to olaparib in breast cancer

Shinya Yamamoto,
Kei Kawashima,
Yoshie Fujiwara,
Shoko Adachi,
Kazutaka Narui,
Chiaki Hosaka,
Rina Takahashi,
Sho Tsuyuki,
Makoto Sugimori,
Miki Tanoshima,
Mahato Sasamoto,
Masanori Oshi,
Akimitsu Yamada,
Chikara Kunisaki,
Itaru Endo

Abstract

A 34-year-old woman with breast cancer and the BRCA2: p.Gln3047Ter was treated with olaparib. After tumor progression, cancer genomic profiling testing revealed the BRCA2 p.Gln3047Ter and p.Gln3047Tyr, with 48.9% and 0.37% allele frequency, respectively. These findings shed light on reversion mutation as a resistance mechanism to olaparib in breast cancer.

19 Feb 2023Submitted to Clinical Case Reports

Show details

Hide details

20 Feb 2023Submission Checks Completed

20 Feb 2023Assigned to Editor

22 Feb 2023Reviewer(s) Assigned

16 Mar 2023Review(s) Completed, Editorial Evaluation Pending

16 Mar 2023Editorial Decision: Revise Minor

07 May 20231st Revision Received

10 May 2023Submission Checks Completed

10 May 2023Assigned to Editor

10 May 2023Review(s) Completed, Editorial Evaluation Pending

30 May 2023Editorial Decision: Accept

Abstract

Peer review status:ACCEPTED